| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.89B | 29.93B | 28.54B | 30.17B | 32.37B | 32.06B |
| Gross Profit | 5.77B | 5.49B | 4.58B | 4.00B | 6.32B | 7.22B |
| EBITDA | 3.74B | 3.46B | 2.60B | 1.95B | 4.25B | 5.16B |
| Net Income | 1.63B | 1.48B | 820.48M | 310.65M | 2.06B | 2.62B |
Balance Sheet | ||||||
| Total Assets | 30.71B | 30.41B | 29.72B | 31.07B | 32.42B | 27.96B |
| Cash, Cash Equivalents and Short-Term Investments | 1.18B | 1.18B | 972.01M | 853.40M | 718.63M | 4.33B |
| Total Debt | 1.33B | 1.49B | 2.21B | 4.33B | 808.15M | 555.36M |
| Total Liabilities | 12.04B | 11.91B | 12.51B | 14.50B | 15.67B | 12.72B |
| Stockholders Equity | 18.68B | 18.50B | 17.21B | 16.57B | 16.75B | 15.24B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.97B | 2.49B | -2.85B | -3.41B | 3.16B |
| Operating Cash Flow | 0.00 | 4.37B | 3.63B | 1.48B | -1.33B | 5.22B |
| Investing Cash Flow | 0.00 | -1.42B | -1.14B | -4.34B | -2.08B | -2.09B |
| Financing Cash Flow | 0.00 | -997.00M | -2.39B | 3.00B | -273.53M | -680.45M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥22.73B | 11.94 | ― | 2.89% | 3.53% | 8.36% | |
73 Outperform | ¥20.61B | 9.78 | ― | 3.79% | 11.19% | 122.83% | |
72 Outperform | ¥17.57B | 13.11 | ― | 4.07% | 18.02% | 18.04% | |
71 Outperform | ¥25.66B | 10.19 | ― | 3.64% | -1.44% | -1.26% | |
66 Neutral | ¥17.11B | 9.04 | ― | 3.27% | 13.09% | 89.45% | |
66 Neutral | ¥16.32B | 11.70 | ― | 2.70% | 1.30% | -5.03% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
Taoka Chemical Co., Ltd. has revised its full-year financial forecasts for the fiscal year ending March 31, 2026. While the company anticipates a slight decrease in net sales due to declining sales in functional chemicals and polymers, it expects an increase in operating and ordinary profits, as well as profit attributable to owners, driven by improved profit margins and reduced expenses.
The most recent analyst rating on (JP:4113) stock is a Buy with a Yen1460.00 price target. To see the full list of analyst forecasts on Taoka Chemical Co., Ltd. stock, see the JP:4113 Stock Forecast page.
Taoka Chemical Co., Ltd. reported a significant increase in its financial performance for the six months ended September 30, 2025, with net sales rising by 17.5% and operating profit surging by 56.6% compared to the previous year. The company’s strong results reflect its improved market positioning and operational efficiency, which are likely to have positive implications for stakeholders.
The most recent analyst rating on (JP:4113) stock is a Buy with a Yen1460.00 price target. To see the full list of analyst forecasts on Taoka Chemical Co., Ltd. stock, see the JP:4113 Stock Forecast page.
Taoka Chemical Co., Ltd. reported a significant increase in its financial performance for the second quarter of the fiscal year ending March 2026. The company achieved a 17.5% increase in net sales and a 56.6% rise in operating profit compared to the previous year. This growth reflects a robust operational performance, enhancing its market position and potentially benefiting stakeholders through increased dividends.
The most recent analyst rating on (JP:4113) stock is a Buy with a Yen1460.00 price target. To see the full list of analyst forecasts on Taoka Chemical Co., Ltd. stock, see the JP:4113 Stock Forecast page.